Results 171 to 180 of about 1,322,023 (308)

Proteomics and HIV [PDF]

PROTEOMICS – Clinical Applications, 2016
Pawel, Ciborowski, Howard S, Fox
openaire   +2 more sources

SMAC mimetics reverse HIV latency by selective activation of the non-canonical NF-κB pathway

Journal of Virus Eradication, 2017
G.C. Sampey, D.M. Irlbeck, D.M. Margolis, R.M. Dunham, E.P. Brownel   +4 more
doaj   +1 more source

Unhealthy Alcohol Use in People Living with HIV: A Narrative Review. [PDF]

Curr HIV/AIDS Rep
Kizito S, Ssewamala FM, Saba SK, Nabunya P, Tutlam N, Mutumba M.   +5 more
europepmc   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Infertility Among Men Living with HIV in Sub-Sahara Africa; Bridging Evidence and Practice Gaps. [PDF]

Res Rep Urol
Adeniyi IA, Shehu UU, Ikuomola EO, Mahmoud TN, Archibong VB, Usman IM.   +5 more
europepmc   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

A Highly Sensitive and Specific Rapid Lateral Flow Assay for the HIV Integrase Strand Transfer Inhibitors Bictegravir, Cabotegravir, and Dolutegravir

AIDS Research and Treatment
Xierong Wei, Ae S. Youngpairoj, Richard Haaland, Chuong Dinh, Hetal K. Patel, Jose J. Perez, Kristin Brown, Thomas H. Vanderford, Jeffrey A. Johnson   +8 more
doaj   +1 more source

Trial of mailed specimen collection for HIV testing in regional Queensland

Australian and New Zealand Journal of Public Health, 2014
William Rutkin, Joseph Debattista, Patrick Martin, John Hooper   +3 more
doaj   +1 more source

Association of Exercise with Body Image Among Older Adults with and Without HIV. [PDF]

J Acquir Immune Defic Syndr
Kulik GL, Wilson MP, Mollner DC, Iriarte E, Fourman LT, Jankowski CM, Erlandson KM.   +6 more
europepmc   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule, Maryam Habib, Rija Khalid, Jessie Tu, Deborah Yoong, Jaris Swidrovich, Wale Ajiboye, Patrick O'Byrne, Ameeta E. Singh, Jean‐Guy Baril, Tatiana Sotindjo, Mark W. Hull, Darrell H. S. Tan   +12 more
wiley   +1 more source